This Article Full Text (PDF) Other Versions of this Article: MCB.01661-07v1 28/8/2659    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Quinlan, M. P. Articles by Settleman, J. PubMed PubMed Citation Articles by Quinlan, M. P. Articles by Settleman, J.

 Previous Article  |  Next Article 

Mol. Cell. Biol. doi:10.1128/MCB.01661-07
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion

Massachusetts General Hospital Cancer Center and Harvard Medical School, 149 13^th Street, Charlestown, MA 02129, USA, Department of Medicine, New York University Medical Center, New York, NY 10016, USA

^* To whom correspondence should be addressed. Email: settleman{at}helix.mgh.harvard.edu.

	Abstract

The three closely related human Ras genes, Hras, Nras, and Kras are all widely expressed, engage a common set of downstream effectors, and can each exhibit oncogenic activity. However, the vast majority of activating Ras mutations in human tumors involve Kras. Moreover, Kras mutations are most frequently seen in tumors of endodermally-derived tissues (lung, pancreas, and colon), suggesting that activated Kras may affect an endodermal progenitor to initiate oncogenesis. Using a culture model of retinoic acid (RA)-induced stem cell differentiation to endoderm, we determined that while activated HrasV12 promotes differentiation and growth arrest in these endodermal progenitors, KrasV12 promotes their proliferation. Furthermore, KrasV12-expressing endodermal progenitors fail to differentiate upon RA treatment and continue to proliferate and maintain stem cell characteristics. NrasV12 neither promotes nor prevents differentiation. A structure-function analysis demonstrated that these distinct effects of the Ras isoforms involve their variable C-terminal domains, implicating compartmentalized signaling, and revealed a requirement for several established Ras effectors. These findings indicate that activated Ras isoforms exert profoundly different effects on endodermal progenitors, and that mutant Kras may initiate tumorigenesis by expanding a susceptible stem/progenitor cell population. These results potentially explain the high frequency of Kras mutations in tumors of endodermal origin.